You are correct he did not clarify “working days” which I would expect. He leaves much to the imagination sometimes and that causes a lot of unrest amongst the shareholders. Hopefully as we move forward they can rectify these issues by getting a better PR process. Once the drug is approved and revenue starts coming in this should be one of their first steps.